Lowering blood pressure reduces renal events in type 2 diabetes

Bastiaan E. De Galan, Vlado Perkovic, Toshiharu Ninomiya, Avinesh Pillai, Anushka Patel, Alan Cass, Bruce Neal, Neil Poulter, Stephen Harrap, Carl Erik Mogensen, Mark Cooper, Michel Marre, Bryan Williams, Pavel Hamet, Giuseppe Mancia, Mark Woodward, Paul Glasziou, Diederick E. Grobbee, Stephen MacMahon, John Chalmers

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recommended thresholds on renal outcomes among 11,140 patients who had type 2 diabetes and participated in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned to fixed combination perindopril-indapamide or placebo, regardless of their BP at entry. During a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21% (P < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both P < 0.003). Effects of active treatment were consistent across subgroups defined by baseline systolic or diastolic BP. Lower systolic BP levels during follow-up, even to <110 mmHg, was associated with progressively lower rates of renal events. In conclusion, BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg. We could not identify a BP threshold below which renal benefit is lost.

Original languageEnglish
Pages (from-to)883-892
Number of pages10
JournalJournal of the American Society of Nephrology
Volume20
Issue number4
DOIs
Publication statusPublished - Apr 1 2009

Fingerprint

Type 2 Diabetes Mellitus
Indapamide
Perindopril
Blood Pressure
Kidney
perindopril drug combination indapamide
Gliclazide
Kidney Diseases
Therapeutics
Vascular Diseases
Placebos

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

De Galan, B. E., Perkovic, V., Ninomiya, T., Pillai, A., Patel, A., Cass, A., ... Chalmers, J. (2009). Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology, 20(4), 883-892. https://doi.org/10.1681/ASN.2008070667

Lowering blood pressure reduces renal events in type 2 diabetes. / De Galan, Bastiaan E.; Perkovic, Vlado; Ninomiya, Toshiharu; Pillai, Avinesh; Patel, Anushka; Cass, Alan; Neal, Bruce; Poulter, Neil; Harrap, Stephen; Mogensen, Carl Erik; Cooper, Mark; Marre, Michel; Williams, Bryan; Hamet, Pavel; Mancia, Giuseppe; Woodward, Mark; Glasziou, Paul; Grobbee, Diederick E.; MacMahon, Stephen; Chalmers, John.

In: Journal of the American Society of Nephrology, Vol. 20, No. 4, 01.04.2009, p. 883-892.

Research output: Contribution to journalArticle

De Galan, BE, Perkovic, V, Ninomiya, T, Pillai, A, Patel, A, Cass, A, Neal, B, Poulter, N, Harrap, S, Mogensen, CE, Cooper, M, Marre, M, Williams, B, Hamet, P, Mancia, G, Woodward, M, Glasziou, P, Grobbee, DE, MacMahon, S & Chalmers, J 2009, 'Lowering blood pressure reduces renal events in type 2 diabetes', Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 883-892. https://doi.org/10.1681/ASN.2008070667
De Galan, Bastiaan E. ; Perkovic, Vlado ; Ninomiya, Toshiharu ; Pillai, Avinesh ; Patel, Anushka ; Cass, Alan ; Neal, Bruce ; Poulter, Neil ; Harrap, Stephen ; Mogensen, Carl Erik ; Cooper, Mark ; Marre, Michel ; Williams, Bryan ; Hamet, Pavel ; Mancia, Giuseppe ; Woodward, Mark ; Glasziou, Paul ; Grobbee, Diederick E. ; MacMahon, Stephen ; Chalmers, John. / Lowering blood pressure reduces renal events in type 2 diabetes. In: Journal of the American Society of Nephrology. 2009 ; Vol. 20, No. 4. pp. 883-892.
@article{07bb3d4d7fa443d094f811320bb6f218,
title = "Lowering blood pressure reduces renal events in type 2 diabetes",
abstract = "BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recommended thresholds on renal outcomes among 11,140 patients who had type 2 diabetes and participated in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned to fixed combination perindopril-indapamide or placebo, regardless of their BP at entry. During a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21{\%} (P < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both P < 0.003). Effects of active treatment were consistent across subgroups defined by baseline systolic or diastolic BP. Lower systolic BP levels during follow-up, even to <110 mmHg, was associated with progressively lower rates of renal events. In conclusion, BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg. We could not identify a BP threshold below which renal benefit is lost.",
author = "{De Galan}, {Bastiaan E.} and Vlado Perkovic and Toshiharu Ninomiya and Avinesh Pillai and Anushka Patel and Alan Cass and Bruce Neal and Neil Poulter and Stephen Harrap and Mogensen, {Carl Erik} and Mark Cooper and Michel Marre and Bryan Williams and Pavel Hamet and Giuseppe Mancia and Mark Woodward and Paul Glasziou and Grobbee, {Diederick E.} and Stephen MacMahon and John Chalmers",
year = "2009",
month = "4",
day = "1",
doi = "10.1681/ASN.2008070667",
language = "English",
volume = "20",
pages = "883--892",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "4",

}

TY - JOUR

T1 - Lowering blood pressure reduces renal events in type 2 diabetes

AU - De Galan, Bastiaan E.

AU - Perkovic, Vlado

AU - Ninomiya, Toshiharu

AU - Pillai, Avinesh

AU - Patel, Anushka

AU - Cass, Alan

AU - Neal, Bruce

AU - Poulter, Neil

AU - Harrap, Stephen

AU - Mogensen, Carl Erik

AU - Cooper, Mark

AU - Marre, Michel

AU - Williams, Bryan

AU - Hamet, Pavel

AU - Mancia, Giuseppe

AU - Woodward, Mark

AU - Glasziou, Paul

AU - Grobbee, Diederick E.

AU - MacMahon, Stephen

AU - Chalmers, John

PY - 2009/4/1

Y1 - 2009/4/1

N2 - BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recommended thresholds on renal outcomes among 11,140 patients who had type 2 diabetes and participated in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned to fixed combination perindopril-indapamide or placebo, regardless of their BP at entry. During a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21% (P < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both P < 0.003). Effects of active treatment were consistent across subgroups defined by baseline systolic or diastolic BP. Lower systolic BP levels during follow-up, even to <110 mmHg, was associated with progressively lower rates of renal events. In conclusion, BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg. We could not identify a BP threshold below which renal benefit is lost.

AB - BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people with diabetes and nephropathy, respectively. We sought to determine the effects of lowering BP below these currently recommended thresholds on renal outcomes among 11,140 patients who had type 2 diabetes and participated in the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned to fixed combination perindopril-indapamide or placebo, regardless of their BP at entry. During a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21% (P < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both P < 0.003). Effects of active treatment were consistent across subgroups defined by baseline systolic or diastolic BP. Lower systolic BP levels during follow-up, even to <110 mmHg, was associated with progressively lower rates of renal events. In conclusion, BP-lowering treatment with perindopril-indapamide administered routinely to individuals with type 2 diabetes provides important renoprotection, even among those with initial BP <120/70 mmHg. We could not identify a BP threshold below which renal benefit is lost.

UR - http://www.scopus.com/inward/record.url?scp=65249111029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249111029&partnerID=8YFLogxK

U2 - 10.1681/ASN.2008070667

DO - 10.1681/ASN.2008070667

M3 - Article

VL - 20

SP - 883

EP - 892

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 4

ER -